SAGE Therapeutics (SAGE) Tops Q4 EPS by 73c

SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($0.55), $0.73 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $77.97 million versus the consensus estimate of $60.01 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• Pfizer lung cancer drug misses survival goal in Phase 3 trial